What compounds target DRD5?

BiohacksAI has identified 19 compounds that interact with DRD5 (dopamine receptor D5). Top compounds include: Pergolide, Bromocriptine, Butaclamol, SCH 23390 [Supplementary Concept], Aripiprazole. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is DRD5 (dopamine receptor D5)?

DRD5 is dopamine receptor D5. It is a molecular target for 19 compounds documented in PubMed bioassay data. UniProt ID: P21918. NCBI Gene ID: 1816.

DRD5

MOLECULAR TARGET

dopamine receptor D5

UniProt: P21918 NCBI Gene: 181619 compounds

DRD5 (dopamine receptor D5) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting DRD5

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	Pergolide	2.08	7
2	Bromocriptine	1.61	4
3	Butaclamol	1.61	4
4	SCH 23390 [Supplementary Concept]	1.61	4
5	Aripiprazole	1.39	3
6	Raclopride	1.39	3
7	Cabergoline	1.10	2
8	Dihydroergotamine	1.10	2
9	Lisuride	1.10	2
10	Lysergic Acid Diethylamide Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is	1.10	2
11	Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent	0.69	1
12	Amoxapine	0.69	1
13	Buspirone	0.69	1
14	Cyproheptadine	0.69	1
15	Loxapine	0.69	1
16	Maprotiline	0.69	1
17	Sulpiride	0.69	1
18	Tetrahydropapaveroline	0.69	1
19	Yohimbine	0.69	1

About DRD5 as a Drug Target

DRD5 (dopamine receptor D5) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented DRD5 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

DRD5 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.